Clinical value of routine therapeutic anti-TNF drug monitoring (TDM) in Inflammatory Bowel Disease (IBD) patients in clinical practice

被引：0
|
作者：
Guirgis, M. [1 ]
Bianchetti, D. [2 ]
Dorta, G. [3 ]
Michetti, P. [1 ]
Maillard, M. [3 ]
机构：
[1] Crohns & Colitis Ctr, Gastroenterol, Lausanne, Switzerland
[2] Univ Lausanne, Gastroenterol & Hepatol, Lausanne, Switzerland
[3] CHU Vaudois, Gastroenterol & Hepatol, CH-1011 Lausanne, Switzerland
来源：
JOURNAL OF CROHNS & COLITIS | 2015年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P317
引用
收藏
页码：S235 / S236
页数：2
相关论文
共 50 条
  • [21] Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease
    Ha, Christina
    Mathur, Jagrati
    Kornbluth, Asher
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 9 (04) : 497 - 505
  • [22] Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus
    Greuter, Thomas
    Maillard, Michel H.
    Juillerat, Pascal
    Michetti, Pierre
    Seibold, Frank
    Mottet, Christian
    Zahnd, Nadine
    Sauter, Bernhard
    Schoepfer, Alain M.
    Rogler, Gerhard
    Vavricka, Stephan R.
    [J]. DIGESTION, 2020, 101 (06) : 683 - 691
  • [23] Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD
    Click, Benjamin
    Barnes, Edward L.
    Cohen, Benjamin L.
    Sands, Bruce E.
    Hanson, John S.
    Rubin, David T.
    Dubinsky, Marla C.
    Regueiro, Miguel
    Gazis, Derek
    Crawford, Julie M.
    Long, Millie D.
    [J]. BMC GASTROENTEROLOGY, 2022, 22 (01)
  • [24] Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD
    Benjamin Click
    Edward L. Barnes
    Benjamin L. Cohen
    Bruce E. Sands
    John S. Hanson
    David T. Rubin
    Marla C. Dubinsky
    Miguel Regueiro
    Derek Gazis
    Julie M. Crawford
    Millie D. Long
    [J]. BMC Gastroenterology, 22
  • [25] Clinical features of tuberculosis infection in inflammatory bowel disease patients on anti-TNF therapy
    Estevez-Gil, M.
    De Castro, M. L.
    Hernandez, V.
    Pineda, J. R.
    Martinez-Cadilla, J.
    Pereira, S.
    Rodriguez-Prada, J-I
    [J]. JOURNAL OF CROHNS & COLITIS, 2017, 11 : S309 - S309
  • [26] Real World Experience in Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Lack of Anti-Drug Antibodies to Vedolizumab and Ustekinumab Compared to Anti-TNF Agents in IBD
    Glassner, Kerri L.
    Oglat, Ayah
    Abraham, Bincy
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S342 - S343
  • [27] Clinical experience with vedolizumab in anti-TNF refractory inflammatory bowel patients
    Christopher, B.
    Aoko, O.
    O'Toole, A.
    Patchett, S.
    Smyth, C.
    Sengupta, S.
    Farrell, R.
    [J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 : S374 - S374
  • [28] An audit of therapeutic drug monitoring (TDM) in clinical practice
    Patel, R.
    Castles, R.
    Rayment, M.
    Barber, T.
    [J]. HIV MEDICINE, 2014, 15 : 123 - 123
  • [29] Therapeutic drug monitoring (TDM) in patients with inflammatory bowel disease (IBD) as an example of the development of theranostics - Personalized precision medicine
    Podstawka, I.
    Skorupa, E.
    Ochocinska, A. M.
    Wlazlo, M.
    Meglicka, M.
    [J]. CLINICA CHIMICA ACTA, 2024, 558
  • [30] Cost-effectiveness of utilising proactive Infliximab therapeutic drug monitoring for inflammatory bowel disease in routine clinical practice
    Steen, J.
    McCormack, M.
    McShane, C.
    Healy, M.
    Crowley, V.
    Kennedy, U.
    Hayes, O.
    Dunne, C.
    Hartery, K.
    McKiernan, S.
    MacCarthy, F.
    Kevans, D.
    [J]. JOURNAL OF CROHNS & COLITIS, 2019, 13 : S307 - S308
12345